CLEVELAND — For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the research pipeline, driven by both dermatologic and rheumatologic advancements, according to a speaker.Although there has not been a single approved drug for cutaneous lupus in 75 years, researchers are hopeful that emerging treatments will soon be available for